110 related articles for article (PubMed ID: 18510026)
1. [Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/TC].
Patriti A; Graziosi L; Baffa N; Pacifico E; Lamprini P; Valiani S; Gullà N; Donini A
Ann Ital Chir; 2007; 78(6):481-5. PubMed ID: 18510026
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
4. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
[TBL] [Abstract][Full Text] [Related]
8. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour.
Graziosi L; Bugiantella W; Cavazzoni E; Cantarella F; Porcari M; Baffa N; Donini A
Ann Ital Chir; 2011; 82(2):125-9. PubMed ID: 21682102
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
Li Y; Yang Y; Lu M; Shen L
Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
[TBL] [Abstract][Full Text] [Related]
10. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
11. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
[TBL] [Abstract][Full Text] [Related]
12. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy.
Kim DH; Oh SJ; Oh CA; Choi MG; Noh JH; Sohn TS; Bae JM; Kim S
J Surg Oncol; 2011 Nov; 104(6):585-91. PubMed ID: 21695697
[TBL] [Abstract][Full Text] [Related]
13. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
Yin LK; Sun XQ; Mou DZ
Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
[TBL] [Abstract][Full Text] [Related]
14. SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients.
Bai L; Guo CH; Zhao Y; Gao JG; Li M; Shen C; Guo YM; Duan XY
Oncol Rep; 2017 Jun; 37(6):3433-3440. PubMed ID: 28498457
[TBL] [Abstract][Full Text] [Related]
15. [Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment].
Ychou M; Tuszinski T; Pignon JP; Bidart JM; Bellet D; Bohuon C; Rougier P
Gastroenterol Clin Biol; 1992; 16(11):848-52. PubMed ID: 1483553
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic value of
Zhang XC; Zhang JH; Wang RF; Fan Y; Fu ZL; Yan P; Zhao GY; Bai YX
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):1071-1077. PubMed ID: 31848507
[TBL] [Abstract][Full Text] [Related]
17. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.
Liang Y; Wang W; Fang C; Raj SS; Hu WM; Li QW; Zhou ZW
Oncotarget; 2016 Aug; 7(31):49565-49573. PubMed ID: 27385101
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
[TBL] [Abstract][Full Text] [Related]
20. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]